Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434277 | 0.82 | GPR119 (0.62) | GPR119AKR1C3MAPT | |
| SCHEMBL10276228 | 0.78 | GPR119 (0.69) | GPR119AKR1C3 | |
| SCHEMBL3486212 | 0.78 | GPR119 (0.69) | GPR119AKR1C3 | |
| SCHEMBL3486603 | 0.77 | GPR119 (0.64) | GPR119AKR1C3 | |
| SCHEMBL3486215 | 0.76 | GPR119 (0.60) | GPR119AKR1C3MAPTEPHX2 | |
| SCHEMBL3486751 | 0.75 | GPR119 (0.76) | GPR119AKR1C3MAPT | |
| SCHEMBL13434279 | 0.74 | GPR119 (0.61) | GPR119KDM4EAKR1C3 | |
| SCHEMBL13434280 | 0.73 | GPR119 (0.62) | GPR119MAPT | |
| SCHEMBL3486452 | 0.72 | GPR119 (1.00) | GPR119 | |
| SCHEMBL3486406 | 0.72 | GPR119 (0.57) | GPR119AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399485-B2 | Acyl bipiperidinyl compounds useful as GPR 119 agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399485-B2 | Acyl bipiperidinyl compounds useful as GPR 119 agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-20100036115-A1 | Novel Compositions for the Delivery of Negatively Charged Molecules | SIRNA THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| EP-1724254-A2 | Novel compositions for the delivery of negatively charged molecules | Sirna Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050234232-A1 | Novel compositions for the delivery of negatively charged molecules | SIRNA THERAPEUTICS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20030073640-A1 | Novel compositions for the delivery of negatively charged molecules | RIBOZYME PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6395713-B1 | CATIONIC LIPIDCATIONIC LIPID | RIBOZYME PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR27, FFAR2 | GPR119 1/4885KDM4E 4135/4885AKR1C3 1257/4885 |
| US-20100036115-A1 | Novel Compositions for the Delivery of Negatively Charged Molecules | PHAX, TARBP1, SNRPE | GPR119 849/4885KDM4E 3777/4885AKR1C3 3178/4885 |
| US-20050234232-A1 | Novel compositions for the delivery of negatively charged molecules | PHAX, TARBP1, SNRPE | GPR119 849/4885KDM4E 3777/4885AKR1C3 3178/4885 |
| US-20030073640-A1 | Novel compositions for the delivery of negatively charged molecules | PHAX, TARBP1, SNRPE | GPR119 849/4885KDM4E 3777/4885AKR1C3 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.